REFERENCES
- Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):11S–18S.
- Walsh T. Prevention of opioid side effects. J Pain Symptom Manage. 1990;5:362–367.
- Walsh T. Oral morphine in chronic cancer pain. Pain. 1984;18:1–11.
- Cameron. Constipation related to narcotic therapy. A protocol for nurses and patients. Cancer Nurs. 1992;15:372–377.
- Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med.1998;12: 375–382.
- McNicol E, Horowicz-Mehler N, Fisk RA, Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231–256.
- Schug SA, Zech D, Grond S. Adverse effects of systemic opioid analgesics. Drug Saf. 1992;7:200–213.
- Bates JJ, Foss JF, Murphy DB. Are peripheral opioid antagonists the solution to opioid side effects? Anesth Analg. 2004;98:116–122.
- Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649–671.
- Liu M, Wittbrodt E. Low-Dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48–53.
- Paulson DM, Kennedy DT, Donovick RA, Alvimopan: an oral, peripherally acting, [mu]-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—a 21-day treatment-randomized clinical trial. J Pain. 2005;6: 184–192.
- Yuan C-S, Wei G, Foss JF, O'Connor M, Karrison T, Osinski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Therap. 2002;300:118–123.
- Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain. 2000;84:105–109.
- Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology. 1985;24: 181–191.
- Yuan C-S, Foss JF, O'Connor M, Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000;67:398– 404.
- Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Therap. 1986;237:945–949.
- Tavani. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci. 1980;27:2211–2217.
- Thomas J, Karver S, Cooney GA, Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332–2343.
- Himmelsbach C. The morphine abstinence syndrome, its nature and treatment. Ann Intern Med. 1941;15:829– 839.
- Christakis NA, Lamont EB, Smith JL, Parkes CM. Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ. 2000;320:469– 473.
- De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16:383–394.